The Canadian National Stock Exchange has not approved nor disapproved
the contents of this press release
VANCOUVER, April 14 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") is pleased to announce the appointment of
Bob Mehr to its Board of Directors.
Mr. Mehr has nearly 20 years of experience in pharmaceutical retail
sales and marketing, as well as hands on management of supply chain and
logistics related to retail pharmacy operations. He is presently the
CEO of a privately held company managing over $20 million in annual
retail pharmacy sales in the Vancouver and Victoria region that he has
owned since 1999.
"Bob brings extensive experience in the pharmaceutical industry to our
board of directors," said Ahmad Doroudian, President and Chief
Executive Officer of Merus. "He has a strong track record in creating
and growing retail pharmacy sales as well as establishing lengthy links
within the medical community, both via health professionals and
patients. Bob will provide real-time and up to date sales and marketing
information as well as feedback from health professionals as it is
particularly related to Merus' products which will be of significant
value in building and growing our business."
Mr. Mehr is a pharmacist registered with the College of Pharmacists of
British Columbia and has a Bachelor of Science degree specializing in
pharmacy from the University of British Columbia.
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition
and licensing of pharmaceutical products. The Company utilizes its
expertise in the North American pharmaceutical markets and its access
to capital to acquire and license niche branded products in Canada and
United States. Merus further enhances the sale and distribution of
these products by introduction of a focused marketing and promotion
This press release may contain forward-looking statements that involve
risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify
forward-looking statements by terminology including "could", "may",
"will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" and the negative of these terms or
other comparable terminology. While these forward-looking statements,
and any assumptions upon which they are based, are made in good faith
and reflect our current judgment regarding the direction of our
business, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this report. Except as required by
applicable law, we do not intend to update any of the forward-looking
statements so as to conform these statements to actual results.
Investors should refer to the risks disclosed in the Company's reports
filed from time to time with securities regulatory authorities.
SOURCE Merus Labs International Inc.
For further information:
Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783